BioSpace News Archive

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that data from its ReOpen1 phase 3 clinical trial will be presented at the American Rhinologic Society (ARS) 68th Annual Meeting in Philadelphia, Pennsylvania on September 9, 2022.

The Business Intelligence Group has named BioHarvest Sciences (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) as a winner of its 2022 Sustainability Leadership Award. The Business Intelligence Group seeks out and rewards those with vision, creativity and persistence, all hallmarks found in the world’s leading companies and individuals across the globe. The awards programs rely on industry leaders who volunteer to read, score and judge nominations.

According to a recent analysis by Emergen Research, the market for neurostimulation devices will be valued USD 13.70 billion by 2027.

Forecast to 2030,’ thoroughly examines the Persistent Depressive Disorder Treatment industry to provide essential data & information for the targeted readers.

Organism’s immune system creates a sub-type of protein called immune repertoire.

Biohacking, also known as do it yourself (DIY) biology, refers to an amorphous and a very broad term that covers a wide range of activities.

The demand within the global chemotherapy-induced myelosuppression treatment market is growing alongside advancements in research pertaining to the bone marrow.

NKGen Biotech, today announced that compassionate use cases of SNK01 + an immune checkpoint inhibitor in patients with advanced sarcoma have been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Annual Congress being held in Paris, France, September 9 – 13, 2022.

The U.S. accounted for 92.5% of the North American pelvic floor diagnostics market in 2021 owing to the rising prevalence of faecal incontinence in the population.

The global cell banking outsourcing market is likely to be driven by the rising demand for biopharmaceutical production targeting novel active sites, stem cell therapy, and gene therapy.